Skip to main content
Clinical Trials/ISRCTN48078312
ISRCTN48078312CompletedNot Applicable

An investigation of the psychological, somatic and related social effects resulting from the use of American skullcap (Scutellaria lateriflora): a randomised placebo-controlled crossover study in healthy volunteers

niversity of Westminster (UK)0 sites42 target enrollmentStarted: September 4, 2009Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
42

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Current inclusion criteria as of 24/03/2011:
  • 1. Aged 18 - 75 years, either sex
  • 2. Good general health
  • 3. Males and females
  • 4. Participants will be volunteers and will have given informed consent
  • 5. Agree to undergo a fingerprick blood test for analysis of liver function pre-, intermediate- and post-intervention
  • Previous inclusion criteria:
  • 1. Symptoms of moderate anxiety, indicated by a cut-off score point for anxiety on the Beck Anxiety Inventory (BAI) between 16 - 25
  • 2. Aged 18 - 75 years, either sex
  • 3. Good general health
  • 4. Males and females
  • 5. Participants will be volunteers and will have given informed consent
  • 6. Agree to undergo a fingerprick blood test for analysis of liver function pre-, intermediate- and post-intervention

Exclusion Criteria

  • Current exclusion criteria as of 24/03/2011:
  • 1. Alcohol, tobacco or recreational drug dependence
  • 2. Known hypersensitivity to any herbal medicines when taken orally
  • 3. Current use or use within the past month of antipsychotic medication, e.g., tranquilisers, antidepressants, or sedatives
  • 4. A history of (diagnosed) severe psychiatric disorders, e.g., clinical depression, bipolar disorder or generalised anxiety disorder
  • 5. Neurological, immunological or endocrinological disorders
  • 6. Liver disease, kidney disease, cancer, diabetes mellitus, malignant hypertension or any other serious medical condition
  • 7. Moderate-high depression, i.e., Hospital Anxiety and Depression Scale (HADS) scores 8 - 21
  • 8. Those currently on, or with a recent history of using, synthetic hormones (other than the contraceptive pill), including sprays or topical corticosteroid analogues
  • 9. Those taking herbs or supplements that many have either a direct or indirect effect on the HPA axis (e.g., dopaminergic, serotonergic, gamma-aminobutyric acid [GABA] -ergic)
  • 10. Pregnancy or lactation
  • 11. Those under 18 or over 75
  • 12. Refusal to undergo blood tests
  • Previous exclusion criteria:
  • 1. Alcohol, tobacco or recreational drug dependence
  • 2. Known hypersensitivity to any herbal medicines when taken orally
  • 3. Current use or use within the past month of antipsychotic medication, e.g., tranquilisers, antidepressants, or sedatives
  • 4. A history of (diagnosed) severe psychiatric disorders, e.g., clinical depression, bipolar disorder or generalised anxiety disorder
  • 5. Neurological, immunological or endocrinological disorders
  • 6. Liver disease, kidney disease, cancer, diabetes mellitus, malignant hypertension or any other serious medical condition
  • 7. Moderate-high depression, i.e., Hospital Anxiety and Depression Scale (HADS) scores 8 - 21
  • 8. Initial scores of above 26 in the BAI, indicating severe anxiety
  • 9. Initial scores below 16 in the BAI, indicating mild anxiety
  • 10. Those currently on, or with a recent history of using, synthetic hormones (other than the contraceptive pill), including sprays or topical corticosteroid analogues
  • 11. Those taking herbs or supplements that many have either a direct or indirect effect on the HPA axis (e.g., dopaminergic, serotonergic, gamma-aminobutyric acid [GABA] -ergic)
  • 12. Pregnancy or lactation
  • 13. Those under 18 or over 75
  • 14. Refusal to undergo blood tests

Investigators

Sponsor
niversity of Westminster (UK)

Similar Trials

American skullcap (Scutellaria... | Clinical Trial